ArticlePharmacoEconomics2021
The Increasing Economic Burden with Additional Steps of Pharmacotherapy in Major Depressive Disorder.
Article in PharmacoEconomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- The efficacy and safety of buprenorphine for the treatment of depression: A systematic review and meta-analysis.Journal of psychiatric research · 2023Pooled it
- The social and healthcare burden of major depressive disorder in adults: an Italian observational cohort study.BMC public health · 2026Observational
- Virtual reality in psychological interventions for mood disorders: a scoping review.BMC psychiatry · 2026Article
- Socioeconomic Status Is Associated With Reward Processing, Interleukin 1β, Striatal Connectivity, and Antidepressant Outcomes in Individuals With Major Depressive Disorder: A CAN-BIND-1 Report.Biological psychiatry global open science · 2026Article
- Repositioning candidate gene approaches in the post-GWAS era: a clinical perspective from psychiatric pharmacogenetics.Frontiers in genetics · 2026Article
- Trend analysis of antidepressant consumption in Italy from 2008 to 2022 in a public health perspective.Scientific reports · 2025Article
- The Humanistic and Economic Burden Associated with Major Depressive Disorder: A Retrospective Cross-Sectional Analysis.Advances in therapy · 2024Article
- Exercise for the Prevention and Treatment of Depression.Current topics in behavioral neurosciences · 2024Review
- The Individual and Societal Burden of Treatment-Resistant Depression: An Overview.The Psychiatric clinics of North America · 2023Review
- Economic burden and antidepressant treatment patterns among patients with major depressive disorder in the United States.Journal of managed care & specialty pharmacy · 2022Observational
- Antidepressant-Like Activity of Solvent Fractions of the Root Bark ofJournal of experimental pharmacology · 2022Article
- The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy Makers.PharmacoEconomics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesMajor depressive disorder (MDD) is a common and serious disorder with significant impact on patients and families. The goal of this retrospective cohort study was to determine the economic burden among patients with MDD stratified by number of treatment lines needed for episode resolution.
methodsTruven Health Analytics MarketScan
resultsA total of 73,597 patients with MDD comprising the commercial (n = 66,459) and Medicare (n = 7138) populations met selection criteria. Patients who completed treatment for their episode with a single line of antidepressant had the lowest total adjusted direct costs (commercial $9975; Medicare $14,628) followed by those who completed with two lines (commercial $11,723; Medicare $15,526) and those treated with three or more lines of antidepressant regimens (commercial $21,259; Medicare $20,964). Patients who completed treatment with two lines as opposed to one incurred significantly higher direct costs (commercial +$1748, p < 0.0001; Medicare +$898, p = 0.0092). Patients who completed treatment with one line had the lowest employment-related costs compared to other groups.
conclusionsThere was an increased economic burden associated with delay of episode resolution as early as the second line compared to the first line in MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.